Pembrolizumab as maintenance therapy for malignant rhabdoid tumor

Pediatr Blood Cancer. 2022 Oct;69(10):e29660. doi: 10.1002/pbc.29660. Epub 2022 Mar 12.

Authors

Rachel Offenbacher^{1

2}, Lara Fabish^{1

2}, Jennifer Oliver-Krasinski³, David M Loeb^{1

2}, Alissa Baker^{1

2}

Affiliations

¹ Department of Pediatrics, Albert Einstein College of Medicine, Bronx, New York, USA.
² Division of Pediatric Hematology, Oncology and Cellular Therapy, Children's Hospital at Montefiore, Bronx, New York, USA.
³ Department of Pathology, Montefiore Medical Center, Bronx, New York, USA.

PMID: 35278029
DOI: 10.1002/pbc.29660

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Humans
Rhabdoid Tumor* / drug therapy
Rhabdoid Tumor* / pathology
SMARCB1 Protein

Substances

Antibodies, Monoclonal, Humanized
SMARCB1 Protein
pembrolizumab